N-[(4S)-2-(2-cyclopropyl-4-pyridinyl)-5,6-dihydro-4H-cyclopenta[c]pyrazol-4-yl]-3,5-difluorobenzamide
C21H18F2N4O — CID 177050074
Data last refreshed: (MolForge compound catalog, from PubChem)
About N-[(4S)-2-(2-cyclopropyl-4-pyridinyl)-5,6-dihydro-4H-cyclopenta[c]pyrazol-4-yl]-3,5-difluorobenzamide
N-[(4S)-2-(2-cyclopropyl-4-pyridinyl)-5,6-dihydro-4H-cyclopenta[c]pyrazol-4-yl]-3,5-difluorobenzamide (PubChem CID 177050074) has the molecular formula C21H18F2N4O and a molecular weight of 380.40 g/mol. Its IUPAC name is N-[(4S)-2-(2-cyclopropyl-4-pyridinyl)-5,6-dihydro-4H-cyclopenta[c]pyrazol-4-yl]-3,5-difluorobenzamide.
Molecular Properties
| Compound Name | N-[(4S)-2-(2-cyclopropyl-4-pyridinyl)-5,6-dihydro-4H-cyclopenta[c]pyrazol-4-yl]-3,5-difluorobenzamide |
|---|---|
| PubChem CID | 177050074 |
| Molecular Formula | C21H18F2N4O |
| Molecular Weight | 380.40 g/mol |
| Exact Mass | 380.14 |
| IUPAC Name | N-[(4S)-2-(2-cyclopropyl-4-pyridinyl)-5,6-dihydro-4H-cyclopenta[c]pyrazol-4-yl]-3,5-difluorobenzamide |
| SMILES | O=C(N[C@H]1CCc2nn(-c3ccnc(C4CC4)c3)cc21)c1cc(F)cc(F)c1 |
| InChI | InChI=1S/C21H18F2N4O/c22-14-7-13(8-15(23)9-14)21(28)25-18-3-4-19-17(18)11-27(26-19)16-5-6-24-20(10-16)12-1-2-12/h5-12,18H,1-4H2,(H,25,28)/t18-/m0/s1 |
| InChIKey | BWXQHIATMDNTQL-SFHVURJKSA-N |
| XLogP | 3.84 |
| TPSA | 59.81 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 4 |
| Rotatable Bonds | 4 |
| Heavy Atoms | 28 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 380.40 |
| LogP ≤ 5 | 3.84 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 4 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 177050074 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.